Fortescue Ltd. Sponsored ADR (OTCMKTS:FSUGY – Get Free Report)’s share price reached a new 52-week low during trading on Wednesday . The stock traded as low as $22.94 and last traded at $22.94, with a volume of 949 shares changing hands. The stock had previously closed at $23.76.
Analyst Upgrades and Downgrades
FSUGY has been the topic of a number of research analyst reports. Jefferies Financial Group raised Fortescue from a “moderate sell” rating to a “hold” rating in a research note on Thursday, August 20th. Zacks Research lowered shares of Fortescue from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 5th. Finally, The Goldman Sachs Group cut shares of Fortescue from a “hold” rating to a “sell” rating and set a $16.90 target price on the stock. in a research report on Thursday, July 2nd. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Fortescue currently has an average rating of “Reduce” and an average price target of $16.90.
Get Our Latest Research Report on Fortescue
Fortescue Stock Performance
About Fortescue
Fortescue is an Australian mining and energy company formerly known as Fortescue Metals Group. The company is best known for producing and exporting iron ore from the Pilbara region of Western Australia, where it operates an integrated network of mines, railways, port facilities and related infrastructure.
Fortescue’s mining business supplies iron ore products to steelmakers in international markets, particularly across Asia. Its operations include hematite mining and processing, along with infrastructure supporting the transportation and shipment of ore from Western Australia.
Through its Fortescue Energy division, the company is also developing renewable energy and green hydrogen projects intended to support industrial decarbonization.
Further Reading
- Five stocks we like better than Fortescue
- These 4 Companies Are Monetizing AI Today
- Quantum and Rare Earths? Implications of the Pasqal/USAR Partnership
- Lockheed’s Stock Hasn’t Priced In Its Own Backlog—Boeing’s Might Already Have
- Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?
Receive News & Ratings for Fortescue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortescue and related companies with MarketBeat.com's FREE daily email newsletter.
